|
Oct 1
|
Aligos Therapeutics Appoints David Perry as Vice President of Business Development
|
|
Sep 30
|
Aligos Therapeutics to Present at Investor Conferences in October
|
|
Sep 24
|
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
|
|
Jul 30
|
Aligos Therapeutics to Announce 2nd Quarter 2024 Financial Results on August 6, 2024
|
|
Jul 29
|
Companies Like Aligos Therapeutics (NASDAQ:ALGS) Could Be Quite Risky
|
|
Jul 10
|
Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB
|
|
Jun 26
|
AbbVie (ABBV) Parkinson's Candidate Faces 2nd FDA Rejection
|
|
Jun 24
|
GSK's Filing for Expanded Use of Jemperli Gets EMA Acceptance
|
|
Jun 21
|
J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease
|
|
Jun 5
|
Aligos Therapeutics Presents Positive Data at the EASL Congress 2024
|
|
Jun 4
|
Here's Why Aligos Therapeutics (ALGS) Is a Great 'Buy the Bottom' Stock Now
|
|
May 22
|
Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024
|
|
May 21
|
Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH
|
|
May 16
|
After Plunging -13.71% in 4 Weeks, Here's Why the Trend Might Reverse for Aligos Therapeutics (ALGS)
|
|
May 9
|
Aligos Therapeutics First Quarter 2024 Earnings: US$0.22 loss per share (vs US$0.54 loss in 1Q 2023)
|
|
May 7
|
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
|
|
Apr 30
|
Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
|
|
Apr 25
|
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
|
|
Apr 25
|
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD
|
|
Apr 9
|
Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
|